ASCO 2018 NSCLC highlights—combination therapy is key-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ASCO 2018 NSCLC highlights—combination therapy is key

Published:2018-10-22 Issue:4 Volume:11 Page:266-271
ISSN:1865-5041
Container-title:memo - Magazine of European Medical Oncology
language:en
Short-container-title:memo

Author:

Gamerith Gabriele,Kocher Florian,Rudzki Jakob,Pircher Andreas

Funder

Verein fuer Tumorforschung, Innsbruck

University of Innsbruck and Medical University of Innsbruck

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://link.springer.com/article/10.1007/s12254-018-0444-7/fulltext.html

Reference18 articles.

1. Oxnard GR, Maddala T, Hubbell E, Aravanis A, Zhang N, Venn O, et al. Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): the Circulating Cancer Genome Atlas (CCGA) Study. J Clin Oncol. 2018;36(18 suppl):LBA8501.

2. Lopes G, Wu Y‑L, Kudaba I, Kowalski D, Cho BC, Castro G, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36(18 suppl):LBA4.

3. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

4. Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez Abreu D, Hussein MA, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1 L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36(18 suppl):LBA9000.

5. Socinski MA, Jotte RM, Cappuzzo F, Orlandi FJ, Stroyakovskiy D, Nogami N, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1 L nonsquamous (NSQ) NSCLC. J Clin Oncol. 2018;36(15 suppl):9002.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression;International Journal of Molecular Sciences;2023-04-09

2. Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade;Briefings in Bioinformatics;2021-04-20

3. MicroRNA‑133a‑3p suppresses malignant behavior of non‑small cell lung cancer cells by negatively regulating ERBB2;Oncology Letters;2021-04-08

4. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells;Oncology Reports;2021-03-22

5. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol;Clinical Lung Cancer;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3